Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC...
31 October 2017 - 3:45AM
Business Wire
New Results from the Phase 2b TIME Trial,
Including the Correlation of Vaccine-Induced Immunogenicity and
Improved Overall Survival, Support Transgene’s Ongoing Clinical
Strategy to Develop TG4010 in Lung Cancer (NSCLC) in Combination
Regimens with Immune Checkpoint Inhibitors (ICIs)
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and
develops viral-based immunotherapies, will be presenting a poster
on additional immunology data generated from the randomized,
placebo-controlled Phase 2b trial (TIME) that evaluated the
combination regimen of TG4010 and chemotherapy in patients with
advanced lung cancer at the Society for Immunotherapy of Cancer
(SITC) Meeting 2017, in National Harbor, Maryland, November
8-12.
Poster title: Immune mechanisms of the response to
TG4010, a viral-based vaccine, in patients with advanced non-small
cell lung carcinoma
• Poster ID: P137
• Date, time, location: Saturday, November 11, 2017, 12:30 –
2:00 pm and 6:30 – 8:00 pm
The abstract will be published on November 7, 2017, on the SITC
website.
All publications on TG4010 can be accessed via www.transgene.fr,
Pipeline>Publications.
About TG4010TG4010 is an immunotherapy that has been
designed to express the coding sequences of the MUC1
tumor-associated antigen and the cytokine, Interleukin-2 (IL2) in a
modified Vaccinia virus (MVA).The combination of TG4010
immunotherapy and chemotherapy has demonstrated significant
efficacy in terms of progression-free survival and overall survival
in patients with advanced stage NSCLC (Quoix et al. Lancet Oncol.
2015). TG4010 is currently being investigated in combination with
nivolumab (ICI) for the 2nd-line treatment of advanced NSCLC
(NCT02823990). A trial in 1st-line treatment of NSCLC is expected
to begin at the end of 2017, evaluating the combination regimen of
TG4010 + nivolumab + chemotherapy in patients whose tumors express
low or undetectable levels of PD-L1.
About TransgeneTransgene (Euronext: TNG), part of
Institut Mérieux, is a publicly traded French biotechnology company
focused on designing and developing targeted immunotherapies for
the treatment of cancer and infectious diseases. Transgene’s
programs utilize viral vector technology with the goal of
indirectly or directly killing infected or cancerous cells. The
Company’s lead clinical-stage programs are: TG4010, a
therapeutic vaccine against non-small cell lung cancer, Pexa-Vec,
an oncolytic virus against liver cancer, and TG4001, a therapeutic
vaccine against HPV-positive head and neck cancers. The Company has
several other programs in clinical development, including TG1050
(chronic hepatitis B) and TG6002 (solid tumors). Transgene is
based in Strasbourg, France, and has additional operations in Lyon,
as well as a joint venture in China. Additional information about
Transgene is available at www.transgene.fr.Follow us on Twitter:
@TransgeneSA
DisclaimerThis press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Document de Référence, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171030005784/en/
Transgene:Lucie Larguier, +33 (0)3 88 27 91
04Director Corporate Communications &
IRinvestorrelations@transgene.frorMedia contacts:Citigate
Dewe RogersonDavid Dible/Marine Perrier, + 44 (0)20 7638
9571transgene@citigatedr.co.uk
TransGaming Inc. (TSXV:TNG)
Historical Stock Chart
From May 2024 to Jun 2024
TransGaming Inc. (TSXV:TNG)
Historical Stock Chart
From Jun 2023 to Jun 2024